Aytu BioPharma, Inc (AYTU) stock
AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3070% below fair value
$2.66+0.84 (+46.15%)
Close on Nov 17, 2026Market cap $28.91MP/E –Yield –
Aytu BioPharma operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Aytu BioPharma's operating cash flow for the twelve months ending Jun 30, 2026 was $3.28M. For fiscal 2026 it was $3.28M. The highest annual figure on record is $3.28M in fiscal 2026.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $3.28M | – |
| FY2025 | Jun 30, 2025 | -$1.94M | – |
| FY2024 | Jun 30, 2024 | -$1.39M | – |
| FY2023 | Jun 30, 2023 | -$5.13M | – |
| FY2022 | Jun 30, 2022 | -$28.82M | – |
| FY2021 | Jun 30, 2021 | -$25.96M | – |
| FY2020 | Jun 30, 2020 | -$28.37M | – |
| FY2019 | Jun 30, 2019 | -$13.83M | – |
| FY2018 | Jun 30, 2018 | -$15.94M | – |
| FY2017 | Jun 30, 2017 | -$13.83M | – |
| FY2016 | Jun 30, 2016 | -$10.66M | – |
| FY2015 | Jun 30, 2015 | -$6.63M | – |
| FY2013 | Aug 31, 2013 | -$37.70K | – |
| FY2012 | Aug 31, 2012 | -$37.85K | – |
| FY2011 | Aug 31, 2011 | -$64.82K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $4.41M | +57.2% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | -$4.18M | – |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $3.68M | +26.5% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | -$618.00K | – |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $2.80M | – |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | -$6.46M | – |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $2.91M | – |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | -$1.19M | – |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -$788.00K | -108.4% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -$254.00K | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$135.00K | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$211.00K | – |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $9.37M | – |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -$2.91M | – |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$2.44M | – |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -$9.15M | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -$7.10M | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -$9.12M | -146.3% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -$8.82M | – |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -$3.79M | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -$6.28M | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $19.70M | -4.4% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -$2.92M | – |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -$7.98M | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -$7.76M | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $20.60M | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -$6.10M | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -$2.99M | – |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | -$3.47M | – |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | -$3.31M | – |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | -$4.30M | – |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | -$2.74M | – |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | -$4.54M | – |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -$4.08M | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | -$3.10M | – |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | -$4.22M | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | -$3.27M | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | -$2.39M | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | -$2.84M | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | -$5.33M | – |
See a number that looks wrong?